Skip to main content

Gyre Therapeutics, Inc.

corporate_fare Company Profile

Gyre Therapeutics, Inc.

GYRE·NASDAQ·Life Sciences·CIK 0001124105

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and sells small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (doing business as Gyre Pharmaceuticals Co., Ltd.), in the People's Republic of China (PRC), and through its U.S. operations based in San Diego, California. In the PRC, Gyre Therapeutics has developed and commercialized ETUARY® (pirfenidone) for fibrotic diseases, which has generated consistent revenue and established the company as a leading participant in treating pulmonary fibrosis. The company has expanded into the United States to advance the clinical development of its pipeline, including F351 (Hydronidone), its lead product candidate for liver fibrosis. Gyre Therapeutics' strategy involves using its existing commercial portfolio to support and reduce risk for late-stage product candidates, extending approved products to treat additional conditions, and creating a diverse pipeline for significant unmet medical needs in fibrosis and related inflammatory diseases. On March 2, 2026, Gyre Therapeutics entered into a Merger Agreement with Cullgen Inc. and Helix Merger Sub Corp., a wholly owned subsidiary of Gyre, under which Merger Sub will merge with Cullgen, with Cullgen becoming a wholly owned subsidiary of Gyre.

Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for GYRE at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Shareholder Vote Sought for Cullgen Merger-Related Preferred Stock Conversion, Enabling Significant Dilution
  • GYRE Subsidiary Submits New Drug Application for Lead Candidate F351 (Hydronidone) in China
  • Annual Report Highlights Strong Pipeline Progress, Strategic Acquisition, and Capital Infusion
  • Gyre Therapeutics Details Significant Revenue Potential for F351 and Cullgen Pipeline Progress at Investor Conference
  • Gyre Therapeutics Forecasts 2026 Revenue of $100.5M-$111M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$116.59M
Net Income
$9.88M
Diluted EPS
$0.02
Op. Cash Flow
$1.01M
Free Cash Flow
-$180K
Gross Profit
$111.17M
Operating Income
$11.49M
Cash & Equivalents
$37.07M
Debt / Equity
0.00×
Net Margin
8.5%
Shares Outstanding
91.31M sh
Source: 10-K · filed 2026-03-13 · accession 0001193125-26-106251
$4.27 +1.43% today
52-week range · as of 2026-11-05 $3.97 – $9.14
Market cap
$485.5M
Volume
240.1K (1.1× avg)
3-mo avg 215K
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GYRE - Filings & News (Page 2)

GYRE
Apr 16, 2026, 4:13 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $7.90
Real-time Price: $4.27 info
Change: -$3.63 (-46%) info
Market Cap: $485.501M info
GYRE
Mar 23, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.78
Real-time Price: $4.27 info
Change: -$2.51 (-37%) info
Market Cap: $485.501M info
GYRE
Mar 13, 2026, 4:31 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $7.56
Real-time Price: $4.27 info
Change: -$3.29 (-43%) info
Market Cap: $485.501M info
GYRE
Mar 12, 2026, 6:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.00
Real-time Price: $4.27 info
Change: -$3.73 (-47%) info
Market Cap: $485.501M info
GYRE
Mar 12, 2026, 6:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $8.00
Real-time Price: $4.27 info
Change: -$3.73 (-47%) info
Market Cap: $485.501M info
GYRE
Mar 11, 2026, 8:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.00
Real-time Price: $4.27 info
Change: -$3.73 (-47%) info
Market Cap: $485.501M info
GYRE
Mar 02, 2026, 9:24 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.20
Real-time Price: $4.27 info
Change: -$3.93 (-48%) info
Market Cap: $485.501M info
GYRE
Mar 02, 2026, 8:29 AM EST
Source: Reuters
Importance Score:
9
Price at Filing: $7.60
Real-time Price: $4.27 info
Change: -$3.33 (-44%) info
Market Cap: $485.501M info
GYRE
Jan 05, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.00
Real-time Price: $4.27 info
Change: -$2.73 (-39%) info
Market Cap: $485.501M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets